Compare Hims and Hers Health Inc (HIMS) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Kinross Gold Corporation — how do they compare? Hims and Hers Health Inc trades at $30.92 (market cap $6.55B), while Kinross Gold Corporation trades at $23.74 (market cap $27.62B). The key difference: Kinross Gold Corporation is far larger — about 4.2× Hims and Hers Health Inc's market cap, and Kinross Gold Corporation pays a 0.69% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Kinross Gold Corporation for 53 Days on average.
| HIMS | KGC | |
|---|---|---|
Market Cap | $6.55B | $27.62B |
Volume | 14,842,814 | 6,347,266 |
Sector | Health | Basic Materials |
52-Week High | $62.76 | $38.06 |
52-Week Low | $14.52 | $22.47 |
Typical Hold Time | 21 Days | 53 Days |
Enterprise Value | $7.25B | $25.70B |
Dividend Yield | — | 0.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $28.06, down 5.01% on the day, reflecting bearish technical signals and negative earnings surprises in recent quarters. The company reported strong revenue growth to $2.35 billion in 2025 but swung to a net loss of -$142 million in 2026, with profitability metrics deteriorating. Multiple securities class action lawsuits filed in October 2026 create significant legal overhangs, while analyst consensus remains cautiously optimistic with a $32.17 price target despite mixed fundamental performance.
The outlook is clouded by legal risks and profitability challenges, though the 15% upside to consensus target suggests potential recovery if execution improves. Key risks include ongoing litigation outcomes and the company's ability to return to sustainable profitability amid competitive pressures in the telehealth sector.
KGC trades at $23.34, up 0.69% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company shows strong fundamentals, with Q2 2026 EPS beating estimates at $0.71 and robust cash flow growth, though recent news highlights production guidance cuts and legal investigations. Valuation ratios remain attractive, with a P/E of 8.87 and EV/EBITDA of 4.59.
The outlook is mixed: strong earnings and cash flow support upside to the $38.80 consensus price target, but risks include cost pressures, production setbacks, and legal scrutiny. Analyst sentiment is bullish with 59% buy ratings, but investors should weigh operational execution against macroeconomic gold price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
